Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Kaltura Inc (KLTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Kaltura Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Kaltura Inc trades at $1.25 (market cap $191.73M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 208.1× Kaltura Inc's market cap. Which is the better fit depends on your goals.
| ALNY | KLTR | |
|---|---|---|
Market Cap | $39.89B | $191.73M |
Sector | Health | Technology |
52-Week High | $491.22 | $1.97 |
52-Week Low | $278.09 | $1.08 |
Enterprise Value | $38.15B | $174.45M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Kaltura (KLTR) trades at $1.28, up 0.79% with a bearish technical outlook despite recent earnings beats. The company shows improving fundamentals with revenue stabilizing around $180M and net losses narrowing from -$68M in 2022 to -$12M in 2025. Recent industry recognitions highlight Kaltura's leadership in AI-powered digital engagement platforms, though negative ROE and high P/B ratio of 41.29 indicate valuation concerns.
While Kaltura demonstrates operational improvement and strong industry positioning, the stock faces headwinds from persistent losses and bearish technical signals. The mixed analyst sentiment (44% buy, 33% hold, 22% sell) reflects uncertainty about profitability timeline. Investment appeal hinges on the company's ability to convert AI innovation into sustainable earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
